Literature DB >> 18491195

Interval period tumor progression: does delayed hepatectomy detect occult metastases in synchronous colorectal liver metastases?

Hiroyuki Yoshidome1, Fumio Kimura, Hiroaki Shimizu, Masayuki Ohtsuka, Atsushi Kato, Hideyuki Yoshitomi, Katsunori Furukawa, Noboru Mitsuhashi, Dan Takeuchi, Ayako Iida, Masaru Miyazaki.   

Abstract

BACKGROUND: Rapid remnant liver recurrence in patients with synchronous colorectal liver metastases (CRLM) is occasionally experienced after simultaneous colorectal and liver resection. We evaluated the tumor progression during interval periods to determine whether delayed hepatic resection detects occult metastases.
METHODS: One hundred thirty-seven patients underwent hepatectomy for synchronous CRLM. Up to 2003, 116 patients underwent simultaneous colorectal and hepatic resection. From 2004 onward, we identified 21 patients undergoing delayed hepatectomy for synchronous CRLM. The tumor progression during interval was determined by a dynamic computed tomography scan.
RESULTS: Median/mean interval between the two evaluations prior to the first and second surgery was 2/2.4 months. The median/mean number of metastases detected at each evaluation was 2/3.3 and 3/4.6, respectively. Nine of the 21 (43%) patients had new detectable metastatic lesions after reevaluation. For 11 of the 21 patients, it was necessary to reconsider planned surgical procedure which was determined prior to colorectal surgery. Hepatic disease-free survival was significantly different between patients undergoing delayed and simultaneous hepatectomy. Multivariate analysis showed that the delayed hepatectomy was a significant independent prognostic factor in hepatic disease-free survival.
CONCLUSION: Tumor progression was recognized and occult metastases were detected after the interval reevaluation. Delayed hepatectomy may be a useful approach to reduce rapid remnant liver recurrence in synchronous CRLM.

Entities:  

Mesh:

Year:  2008        PMID: 18491195     DOI: 10.1007/s11605-008-0540-9

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  33 in total

1.  Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study.

Authors:  Daniel Jaeck; Hiroshi Nakano; Philippe Bachellier; Keiichiro Inoue; Jean-Christophe Weber; Elie Oussoultzoglou; Philippe Wolf; Marie-Pierre Chenard-Neu
Journal:  Ann Surg Oncol       Date:  2002-06       Impact factor: 5.344

2.  Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.

Authors:  Mehdi Karoui; Christophe Penna; Mohamed Amin-Hashem; Emmanuel Mitry; Stephane Benoist; Brigitte Franc; Philippe Rougier; Bernard Nordlinger
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

3.  Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation.

Authors:  Masami Minagawa; Junji Yamamoto; Tomoo Kosuge; Yutaka Matsuyama; Shin-Ichi Miyagawa; Masatoshi Makuuchi
Journal:  Arch Surg       Date:  2007-03

Review 4.  Surgery for colorectal liver metastases with hepatic lymph node involvement: a systematic review.

Authors:  M S Rodgers; J L McCall
Journal:  Br J Surg       Date:  2000-09       Impact factor: 6.939

5.  Liver resection for colorectal metastases.

Authors:  Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

6.  Hepatic resection for colorectal metastases: analysis of prognostic factors.

Authors:  S Ambiru; M Miyazaki; T Isono; H Ito; K Nakagawa; H Shimizu; K Kusashio; S Furuya; N Nakajima
Journal:  Dis Colon Rectum       Date:  1999-05       Impact factor: 4.585

7.  Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system.

Authors:  S Iwatsuki; I Dvorchik; J R Madariaga; J W Marsh; F Dodson; A C Bonham; D A Geller; T J Gayowski; J J Fung; T E Starzl
Journal:  J Am Coll Surg       Date:  1999-09       Impact factor: 6.113

8.  Immunohistochemically detected hepatic micrometastases predict a high risk of intrahepatic recurrence after resection of colorectal carcinoma liver metastases.

Authors:  Naoyuki Yokoyama; Yoshio Shirai; Yoich Ajioka; Shigenori Nagakura; Takeyasu Suda; Katsuyoshi Hatakeyama
Journal:  Cancer       Date:  2002-03-15       Impact factor: 6.860

9.  Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

Authors:  René Adam; Gerard Pascal; Denis Castaing; Daniel Azoulay; Valerie Delvart; Bernard Paule; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

10.  Results of R0 resection for colorectal liver metastases associated with extrahepatic disease.

Authors:  Dominique Elias; Lucas Sideris; Marc Pocard; Jean-Francois Ouellet; Valérie Boige; Philippe Lasser; Jean-Pierre Pignon; Michel Ducreux
Journal:  Ann Surg Oncol       Date:  2004-03       Impact factor: 5.344

View more
  16 in total

1.  Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases.

Authors:  Hideki Suzuki; Takaaki Fujii; Takayuki Asao; Soichi Tsutsumi; Satoshi Wada; Kenichiro Araki; Norio Kubo; Akira Watanabe; Mariko Tsukagoshi; Hiroyuki Kuwano
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

2.  Timing of resection for synchronous liver metastases from colorectal cancer.

Authors:  Masaki Kaibori; Shigeyoshi Iwamoto; Morihiko Ishizaki; Kosuke Matsui; Takamichi Saito; Kazuhiko Yoshioka; Yoshinori Hamada; A Hon Kwon
Journal:  Dig Dis Sci       Date:  2010-01-29       Impact factor: 3.199

3.  Treatment strategy for colorectal cancer with resectable synchronous liver metastases: Is any evidence-based strategy possible?

Authors:  Luca Viganò
Journal:  World J Hepatol       Date:  2012-08-27

Review 4.  The management of rectal cancer with synchronous liver metastases: a modern surgical dilemma.

Authors:  A A P Slesser; A Bhangu; G Brown; S Mudan; P P Tekkis
Journal:  Tech Coloproctol       Date:  2012-09-26       Impact factor: 3.781

Review 5.  Curative strategies for liver metastases from colorectal cancer: a review.

Authors:  Nicholas Zdenkowski; Stanley Chen; Andre van der Westhuizen; Stephen Ackland
Journal:  Oncologist       Date:  2012-01-10

6.  Plasma chitinase 3-like 1 is persistently elevated during first month after minimally invasive colorectal cancer resection.

Authors:  H M C Shantha Kumara; David Gaita; Hiromichi Miyagaki; Xiaohong Yan; Sonali Ac Hearth; Linda Njoh; Vesna Cekic; Richard L Whelan
Journal:  World J Gastrointest Oncol       Date:  2016-08-15

7.  Simultaneous Pure Laparoscopic Resection of Primary Colorectal Cancer and Synchronous Liver Metastases: A Single Institution Experience with Propensity Score Matching Analysis.

Authors:  Arpad Ivanecz; Bojan Krebs; Andraz Stozer; Tomaz Jagric; Irena Plahuta; Stojan Potrc
Journal:  Radiol Oncol       Date:  2017-11-01       Impact factor: 2.991

Review 8.  Contemporary surgical management of synchronous colorectal liver metastases.

Authors:  Danielle Collins; Heidi Chua
Journal:  F1000Res       Date:  2017-04-28

9.  Plasma levels of the proangiogenic protein CXCL16 remains elevated for 1 month after minimally invasive colorectal cancer resection.

Authors:  H M C Shantha Kumara; Erica Pettke; Abhinit Shah; Xiaohong Yan; Vesna Cekic; Melissa Alvarez Downing; Nipa Dilip Gandhi; Richard L Whelan
Journal:  World J Surg Oncol       Date:  2018-07-07       Impact factor: 2.754

10.  Which strategy is better for resectable synchronous liver metastasis from colorectal cancer, simultaneous surgery, or staged surgery? Multicenter retrospective analysis.

Authors:  Bong-Hyeon Kye; Suk-Hwan Lee; Woon Kyung Jeong; Chang Sik Yu; In Ja Park; Hyeong Rok Kim; Jin Kim; In Kyu Lee; Ki-Jea Park; Hong-Jo Choi; Ho Young Kim; Jeong-Heum Baek; Yoon-Suk Lee
Journal:  Ann Surg Treat Res       Date:  2019-10-01       Impact factor: 1.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.